Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor
OMER and MIGDAL HA'EMEK, Israel, August 3 /PRNewswire-FirstCall/ --
Medigus Ltd. (TASE: MDGS) a leading developer of endoscopic and visualization
medical devices, and Tower Semiconductor, Ltd. (Nasdaq: TSEM , TASE: TASE:
TSEM), a leading global specialty foundry, today announced successful
Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
Study Presented at 2009 AACR Meeting Highlights Potential Therapeutic Approach to Treat Patients Unresponsive to Erbitux and Vectibix
DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treat...
Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
ROCKVILLE, Md., April 7 /PRNewswire/ -- Glycotex, Inc. today announced the completion of a scheduled interim analysis in a Phase II study evaluating the effect of investigational GLYC-101 gel on complete wound closure and cosmetic outcomes in cosmetic surgery patients undergoing carbon dioxide las...
Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
FORT WORTH, Texas, March 16 /PRNewswire/ -- Healthpoint today announced that it has initiated a Phase II clinical trial investigating the efficacy of HP802-247 in venous leg ulcers. HP802-247 is a topical spray containing living keratinocytes and fibroblasts. The study is designed to determine the...
Drug Development Program Started Based on CAP(R) Human Cell Line
COLOGNE, Germany, March 3 /PRNewswire/ --
- New Platform May Provide Solutions for Many RA-Patients Around the World
Alloksys Life Sciences BV (Bunnik, The Netherlands), CEVEC
Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The
Netherlands) announce the sta...
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results based
on extended follow up of patients from the large, international Phase III VISTA(1) trial showing continued survival improvement for patients with previously untreated multiple myeloma...
Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology
Company today reported updated results from two large, multi-center,
randomized Phase III clinical trials of VELCADE based
combinations for the
induction treatment of transplant-eligible patients with previously untreated
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
SAN FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The Takeda Oncology
Company today reported the Phase I results from a randomized, multi-center,
Company-sponsored Phase I/II study of VELCADE, dexamethasone, cyclophosphamide
and lenalidomide (VcDCR) in patients with previously untreated multiple
New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults
SAN FRANCISCO, Nov. 19 /PRNewswire/ -- Posit Science Corporation
researcher, Dan Tinker, presented evidence at the Society for Neuroscience
Annual Conference in Washington, DC this week indicating that cognitive
training may benefit Baby Boomers. The computerized brain plasticity-based
Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
ORMD 0901 is Being Developed as an Oral Dosage Form of a GLP1-analog Aimed at Improving Glycemic Control in Adults With Type 2 Diabetes
JERUSALEM, Israel, September 16 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral drug delivery
RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
-- Regulatory applications to be submitted worldwide for RAD001 first submissions filed in the Hidden List US, EU and Switzerland
-- Data showing that RAD001 more than doubles time without tumor growth and reduced risk of disease progression by 70% now published in The...
Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
FORT WORTH, Texas, July 30 /PRNewswire/ -- Wound Care Innovations, LLC,
a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board:
WNDM), announced today an evidence based
study with a NE podiatric clinic
evaluating the clinical performance of their advanced wound care collagen
First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval
Test Developed and Validated by Columbia University Medical Center Based
on Rosetta Genomics' Proprietary MicroRNA Technology
The Test Differentiates Squamous From Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying Squamous-Cell Carcinoma of the Lung With Sensitivity...
Wound Management Technologies, Inc. Announces Evidence Based Study
FORT WORTH, Texas, June 3 /PRNewswire-FirstCall/ -- Wound Care
Innovations, LLC, a subsidiary of Wound Management Technologies, Inc.
(formerly MB Software Corporation (OTC Bulletin Board: MBSB)) announced
today that it will begin an evidence based
study evaluating the clinical
performance of t...
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda
Oncology Company, today announced the presentation of results from three
clinical trials of VELCADE based
therapies that showed consistently high
complete remission(1) (CR) rates in patients with newly diagnosed multiple
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
-- IFM presents updated results from Phase III clinical trial --
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda
Oncology Company, today announced the presentation of updated results from
a 482 patient, multi-center, randomized Phase III clinical trial, comparing
New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
- Five Oral Presentations at ASCO Annual Meeting Will Further Demonstrate
the Strength of VELCADE Combinations in Front-line Multiple Myeloma -
CAMBRIDGE, Mass., May 16 /PRNewswire/ -- Millennium Pharmaceuticals,
The Takeda Oncology Company, today announced that new data from VELCADE
Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics
Demonstration Signifies Completion of First Disease Database for the VentriPoint Diagnostic System
SEATTLE, April 29 /PRNewswire/ -- VentriPoint Diagnostics today
announced that Knowledge Based
Reconstruction (KBR) enables accurate three
dimensional reconstruction of righ...
Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling
Data presented at AACR 2008
SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Systems Medicine LLC
(SM), a wholly owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq
and MTAX: CTIC), presented data from a preclinical study demonstrating that
the Company's experimental d...
Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
The Laboratory-Developed Test is Designed to Differentiate Squamous From
Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying Squamous Cell
Carcinoma of the Lung With Sensitivity of 96 Percent and Specificity of 90 Percent.
Accurate Diagnosis is Importa...
Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
CARMIEL, Israel, Jan. 22 /PRNewswire-FirstCall/ -- Protalix
BioTherapeutics, Inc. (Amex: PLX ), today announced that it has achieved
proof of concept results in an animal study conducted as part of its
Acetylcholinesterase (AChE) Program. The Acetylcholinesterase (AChE)
Program is being condu...
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
- Three large, randomized Phase III trials of VELCADE in front-line
multiple myeloma to be featured as oral presentations at the American Society of Hematology (ASH) Annual Meeting -
CAMBRIDGE, Mass., Nov. 26 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq:...
BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
BRUSSELS, Belgium and BRISBANE, Calif., Nov. 15 /PRNewswire/ -- BiPar
Sciences, Inc., a privately held biopharmaceutical company developing novel
cancer therapies, today announced it has initiated a Phase 2 study of its
lead PARP inhibitor, BSI-201, in patients with triple-negative breast
Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
BOULDER, Colo., Oct. 22 /PRNewswire/ -- Sciona, Inc., a leader in the
science of nutrigenetics, today announced the results of a pivotal study
published by Nutrition Journal, which demonstrates substantial advances in
long term weight management and blood glucose levels as a result of
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
- Millennium on track to file sNDA in first quarter 2008 -
CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced that the interim
analysis results of the large, international Phase III VISTA(1) trial in
patients with newly...
Othera Pharmaceuticals Announces Upcoming Presentation Based Upon
Expanded Understanding of Lead Compound Mechanism of Action
EXTON, Pa.--(BUSINESS WIRE)--Apr 19, 2007 - Othera Pharmaceuticals,
Inc. today announced that Dr. Shaker Mousa, Professor of
Pharmacology and Executive Vice President and Chairman of the
Pharmaceutical Research Institute at Albany College of Pharmacy,
will present new preclinical data detailing the...
Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer
Patients Treated with Therapy Based on Ratiometric Dosing
Phase I results for CPX-1 presented at ASCO confirm safety findings
and demonstrate clinical benefit in more than 70% of patients with
colorectal and other types of cancer.
PRINCETON, N.J., June 04, 2007 /PRNewswire/ -- Celator
Pharmaceuticals announced positive safety and efficacy results from
Velcade (bortezomib) for Injection Based Therapies Achieved
Survival Rates as High as 100 Percent in Newly Diagnosed Multiple
-- 100 percent response rate achieved with VELCADE, lenalidomide
KOS, Greece, June 28 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported on the
presentation of results from four clinical trials of VELCADE based
therapies that showed consist...
Velcade (Bortezomib) for Injection Based Therapies Produced
Complete Remission Rates as High as 54 Percent in Patients With
Previously Treated Multiple Myeloma
- 100 percent of patients treated with VELCADE, cyclophosphamide,
and prednisone alive at one year -
KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. today reported on the presentation of results
from clinical trials of VELCADE based
therapies that showed high
Velcade (bortezomib) for Injection Based Induction Therapy
Delivered High Post-Transplant Complete Remission Rate, a Critical
Marker for Increased Overall Survival
- New Data from Phase III Intergroupe Francophone du Myelome (IFM)
Trial Presented During IMW -
CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ --
Millennium Pharmaceuticals, Inc. today reported that new data were
presented on the comparative Phase III clinical trial evaluating a
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
...nt for the treatment of EGFR-expressing, metastatic colorectal carcinoma is based
on progression-free survival. Currently no data are available that demonstr...tatements
This news release contains forward-looking statements that are based
on management's current expectations and beliefs and are subject to a numbe...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...ncoGenex Pharmaceuticals, Inc.
Isis' revenue fluctuates based
on the nature and timing of payments under agreements with the Company's pa...nts reflect the good faith judgment of its management, these statements are based
only on facts and factors currently known by Isis. As a result, you are ca...
Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
... medical needs, we are looking to expand both the targets and the realm of possible treatments that can benefit people living with diabetes."
in San Diego, GNF was founded in 1999. Funded by the Novartis Research Foundation, its mission is to develop and apply innovative technologies to the ...
Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
...tigators around the country. CCNC brings the best of medical science and cancer care support services together in one pleasant, convenient, community- based
organization. For more information, visit www.cancercentersofnc.com
CCNC is united in healing with US Oncology, supporting the nation's foremos...
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
...rug therapies for osteoporosis and women's health. Radius has raised $106.5 million in private equity financing since its establishment in 2003 and is based
in Cambridge, Massachusetts.
Contact: Nick Harvey
Chief Financial Officer
NewCardio Announces Master Services Agreement With Dedicated Phase I
... future events or conditions. These statements are based
on current expectations, estimates and projections about our business based
on currently available information and assumptions...he forward-looking statements contained herein are based
are reasonable, any of those assumptions could pro...
Labopharm files New Drug Submission with Health Canada for novel antidepressant
...rmulation and we are currently in discussions with potential partners to support the commercialization of our product in Canada."
Labopharm's NDS is based
on data from five pivotal pharmacokinetic studies and the positive results from a North American Phase III placebo controlled clinical trial (study 04...
NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
...Inc has successfully completed a Phase I/IIa clinical study with a candidate H5N1 influenza VLP vaccine and is currently in Phase II trials with a VLP based
seasonal flu vaccine candidate. The Company plans to initiate a Phase II study with its Seasonal Flu vaccine candidate in the elderly population duri...
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
...ernational) with a passcode of 26851386.
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based
on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved...
Study Shows Brain Fitness can Save Medicare Billions
...r took part in computerized brain fitness exercises. Each intervention was based
on a total of ten hours of training over one initial six-week period. Parti...ncy for Healthcare Research and Quality (AHRQ) to predict healthcare costs, based
on massive correlation of actual healthcare costs to SF-36 scores.